To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

676 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-20

Study Completion Date

2019-04-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to evaluate real-world safety, effectiveness and appropriate use of Micatrio® Combination Tablets treatment in patients with hypertension

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Add-on to Micamlo BP Trial

NCT01975246

Hypertension

COMPLETED PHASE3

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

NCT01911780

Hypertension

COMPLETED PHASE3

Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

NCT01286558

Hypertension

COMPLETED PHASE3

Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

NCT01204398

Hypertension

COMPLETED PHASE3

Filtered Trial for Telmisartan 40mg Non-responder

NCT00550953

Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-interventional study based on newly collected data. The study will consist of a baseline visit and follow-up visits at Week 4, 8, 12, 24, 36 and 52 for patients who have newly initiated Micatrio® Combination Tablets. The patients will be followed up until discontinuation of Micatrio® Combination Tablets treatment or the end of study.

All patients administrated Micatrio® Combination Tablets after the launch at the sites contracted with the sponsor will be registered.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T80/A5/H12.5 FDC

Patients with hypertension

T80/A5/H12.5 FDC

Intervention Type DRUG

Drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

T80/A5/H12.5 FDC

Drug

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MICATRIO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are prescribed with Micatrio® Combination Tablets by the discretion of investigators based on the Japanese package insert
* Patients who have never been treated with Micatrio® Combination Tablets before enrolment